Ted C. Nark is Director at Amneal Pharmaceuticals, Inc. (AMRX). They have made 3 open-market trades across 2 companies since 2007, most recently 2026-05-07.
CIK 0001316851
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $120K since 2019, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AMRX | 325,848 | $6.2M |
| FTD | 93,256 | $16K |
| GAIA | 2,507 | $3K |
| RSOL | 5,505 | — |
| Total | $6.3M |
Shares reported on the most recent Form 4, priced at the 2026-05-08 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.